Aclaris Therapeutics (ACRS) Net Cash Flow (2014 - 2026)

Aclaris Therapeutics' Net Cash Flow history runs 13 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 50.34% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was -$1.7 million, a 69.06% increase from a year earlier, with the FY2025 full-year figure at -$4.6 million, up 69.89% from the prior year.
• Net Cash Flow grew to $8.7 million in Q1 2026 per ACRS's latest filing, from -$5.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $31.9 million in Q2 2022 and bottomed at -$40.3 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$555000.0 (2023), against an average of -$1.5 million.
• Across the five-year window, Net Cash Flow sank 2854.3% in 2024 and soared 243.35% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$16.4 million in 2022, then soared by 105.12% to $838000.0 in 2023, then sank by 2854.3% to -$23.1 million in 2024, then jumped by 77.05% to -$5.3 million in 2025, then surged by 264.27% to $8.7 million in 2026.
• Per Business Quant, the three latest ACRS Net Cash Flow figures stand at $8.7 million (Q1 2026), -$5.3 million (Q4 2025), and -$146000.0 (Q3 2025).